Metastatic Cancers clinical trials

Explore recruiting metastatic cancers clinical trials.

Recruiting metastatic cancers studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Cancers trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

MOST Plus (My Own Specific Treatment) - A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors

France

Therapeutic exploratory (Phase II) EU CTIS Study details

MegaMOST - A multicenter, open-label, biology driven, Phase II study evaluating the activity of anti-cancer treatments targeting tumor molecular alterations/characteristics in advanced / metastatic tumors

France

Therapeutic exploratory (Phase II) EU CTIS Study details

First-in-Human Dose Study of IOA-244 in patients with advanced or metastatic cancers.

Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers

Poland, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

ADCX-020 for the treatment of patients with locally advanced or metastatic cancers

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors

Germany, Spain, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Metastatic Cancers trials by city

Metastatic Cancers in Toronto Metastatic Cancers in Vancouver Metastatic Cancers in Montreal Metastatic Cancers in Calgary Metastatic Cancers in Edmonton Metastatic Cancers in Ottawa Metastatic Cancers in Winnipeg Metastatic Cancers in Quebec City Metastatic Cancers in Hamilton Metastatic Cancers in Kitchener Metastatic Cancers in London Metastatic Cancers in Halifax Metastatic Cancers in New York Metastatic Cancers in Los Angeles Metastatic Cancers in Chicago Metastatic Cancers in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease